miR-330-3p和AXIN1295aa在胃癌组织中的表达及临床意义

李阳; 王凯; 宋宗工

doi:10.16766/j.cnki.issn.1674-4152.003911

miR-330-3p和AXIN1295aa在胃癌组织中的表达及临床意义

doi: 10.16766/j.cnki.issn.1674-4152.003911

1.
新乡医学院附属南阳市第二人民医院消化内科，河南南阳 473012
2.
新乡医学院附属南阳市第二人民医院微创外科

基金项目:

河南省医学科技攻关计划联合共建项目 LHGJ20210977

详细信息

作者简介:
宋宗工，E-mail: songzonggong@sina.com

中图分类号: R735.2 R730.43
计量
- 文章访问数: 6
- HTML全文浏览量: 3
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2024-02-26
- 网络出版日期: 2025-05-14

Expression and clinical significance of miR-330-3p and AXIN1295aa in gastric cancer

1.
Gastroenterology, the Affiliated Nanyang Second General Hospital, Xinxiang Medical University, Nanyang, Henan 473012, China

摘要

摘要: 目的微小核糖核酸(miRNA)和Wnt/β-catenin信号通路在肿瘤的发生发展中发挥重要作用，本研究旨在探讨微小RNA-330-3p(miR-330-3p)和轴抑制蛋白1295aa(AXIN1295aa)表达对胃癌的影响。方法选取2020年1—10月南阳市第二人民医院收治的胃癌患者130例。采用qRT-PCR检测胃癌组织中miR-330-3p和AXIN1295aa mRNA的表达；采用免疫组化检测AXIN1295aa蛋白表达水平。结果胃癌组织中miR-330-3p与AXIN1295aa mRNA表达水平(1.79±0.24、0.52±0.10)明显高于正常胃黏膜组织(1.05±0.14、0.11±0.03, t=30.382、40.575，均P < 0.05)。胃癌组织中AXIN1295aa蛋白阳性率(70.77%)明显高于正常胃黏膜组织(37.69%, x²=16.426，P < 0.001)。miR-330-3p和AXIN1295aa表达水平在不同肿瘤直径、分化程度、TNM分期、淋巴结转移、侵及浆膜层患者间比较差异均有统计学意义(P < 0.05)。不同miR-330-3p、AXIN1295aa表达水平胃癌患者3年生存率差异均有统计学意义(P < 0.01)。miR-330-3p、AXIN1295aa联用对胃癌患者3年死亡风险具有较高的预测价值(AUC=0.846)。胃癌组织中miR-330-3p与AXIN1295aa mRNA表达水平呈正相关关系。结论胃癌组织中miR-330-3p和AXIN1295aa高表达，与患者术后生存密切相关，可作为潜在的预后评估指标。
- 胃癌 /
- 微小RNA-330-3p /
- 轴抑制蛋白1295aa /
- 预后评估
Abstract: Objective miRNA and the Wnt/β-catenin signaling pathway play important roles in the occurrence and development of tumors. This study aims to explore the effects of miRNA-330-3p (miR-330-3p) and axis suppressor protein 1295aa (AXIN1295aa) expression on gastric cancer. Methods A total of 130 patients with gastric cancer admitted to Nanyang Second General Hospital from January to October 2020 were selected. The mRNA expression of miR-330-3p and AXIN1295aa in gastric cancer tissues was detected by qRT-PCR. The expression level of AXIN1295aa protein was detected by immunohistochemistry. Results The expression levels of miR-330-3p and AXIN1295aa mRNA in gastric cancer tissue were significantly higher (1.79±0.24 and 0.52±0.10) than those in normal gastric mucosal tissue (1.05±0.14 and 0.11±0.03, t=30.382, 40.575, P < 0.05). The positivity rate of AXIN1295aa protein in gastric cancer tissue was 70.77%, significantly higher than that in normal gastric mucosal tissue 37.69% (x²=16.426, P < 0.001). There were statistically significant differences in the expression levels of miR-330-3p and AXIN1295aa among patients with different tumor diameter, differentiation degree, TNM staging, lymph node metastasis, and invasion of the serosal layer (P < 0.05). There was a statistically significant difference in the 3-year survival rate of gastric cancer patients with different levels of miR-330-3p and AXIN1295aa expression (P < 0.01). The combination of miR-330-3p and AXIN1295aa had a high predictive value for 3-year mortality risk in gastric cancer patients (AUC=0.846). There was a positive correlation between miR-330-3p and AXIN1295aa mRNA expression levels in gastric cancer tissue. Conclusion The high expression of miR-330-3p and AXIN1295aa in gastric cancer tissues is closely related to postoperative survival of patients, and can be used as a potential prognostic indicator.
- Gastric cancer /
- microRNA-330-3p /
- Axis inhibitor protein 1295aa /
- Prognosis evaluation

HTML全文

图 1 正常胃黏膜和胃癌组织HE染色及AXIN1295aa蛋白免疫组化染色(×200)

注：A示正常胃黏膜HE染色；B示胃癌组织HE染色；C示正常胃黏膜免疫组化染色阴性；D示正常胃黏膜免疫组化染色弱阳性；E示正常胃黏膜免疫组化染色阳性；F示正常胃黏膜免疫组化染色强阳性；G示胃癌组织免疫组化染色阴性；H示胃癌组织免疫组化染色弱阳性；I示胃癌组织免疫组化染色阳性；J示胃癌组织免疫组化染色强阳性。黑色箭头指示蛋白阳性表达。

Figure 1. HE staining and AXIN1295aa protein immunohistochemical staining of normal gastric mucosa and gastric cancer tissue (×200)

下载: 全尺寸图片幻灯片

图 2 miR-330-3p表达与胃癌患者生存情况的Kaplan-Meier曲线分析

Figure 2. Kaplan Meier curve analysis of miR-330-3p expression and survival of patients with gastric cancer

下载: 全尺寸图片幻灯片

图 3 AXIN1295aa表达与胃癌患者生存情况的Kaplan-Meier曲线分析

Figure 3. Kaplan Meier curve analysis of AXIN1295aa expression and survival of patients with gastric cancer

下载: 全尺寸图片幻灯片

图 4 miR-330-3p与AXIN1295aa预测胃癌患者死亡风险的ROC曲线

Figure 4. ROC curve of miR-330-3p and AXIN1295aa in predicting the risk of death in gastric cancer patients

下载: 全尺寸图片幻灯片

表 1 胃癌组织和正常胃黏膜组织中miR-330-3p与AXIN1295aa mRNA表达水平比较(x±s)

Table 1. Comparison of miR-330-3p and AXIN1295aa mRNA expression levels in gastric cancer and normal gastric mucosal tissues (x ±s)

组别	例数	miR-330-3p	AXIN1295aa mRNA
正常胃黏膜组织	130	1.05±0.14	0.11±0.03
胃癌组织	130	1.79±0.24	0.52±0.10
t值		30.382	40.575
P值		< 0.001	< 0.001

下载: 导出CSV

表 2 胃癌组织中miR-330-3p与AXIN1295aa表达与临床病理特征的关系(x ±s)

Table 2. Relationship between miR-330-3p and AXIN1295aa expression and clinical pathological characteristics in gastric cancer tissue (x ±s)

项目	例数	miR-330-3p	统计量	P值	AXIN1295aa	统计量	P值
性别
男性	70	1.74±0.21	0.242^a	0.826	0.55±0.11	0.205^a	0.841
女性	60	1.81±0.27			0.49±0.07
年龄(岁)
< 60	62	1.73±0.23	0.391^a	0.748	0.53±0.12	0.145^a	0.903
≥60	68	1.82±0.26			0.50±0.07
病变部位
胃窦	66	1.84±0.31	0.462^b	0.675	0.57±0.11	0.182^b	0.906
胃体	38	1.76±0.26			0.53±0.09
胃底贲门	26	1.79±0.21			0.49±0.07
肿瘤直径(mm)
< 50	56	1.39±0.18	7.850^a	0.028	0.41±0.05	6.347^a	0.037
≥50	74	2.28±0.41			0.68±0.14
分化程度
低分化	50	2.53±0.38	8.611^a	0.024	0.75±0.16	14.508^a	0.001
中高分化	80	1.37±0.19			0.21±0.03
TNM分期
Ⅰ~Ⅱ	78	1.34±0.21	10.580^a	0.010	0.24±0.03	17.237^a	< 0.001
Ⅲ~Ⅳ	52	2.71±0.40			0.79±0.15
淋巴结转移
有	62	2.58±0.38	9.563^a	0.016	0.71±0.19	15.829^a	< 0.001
无	68	1.36±0.19			0.27±0.05
侵及浆膜层
有	54	2.75±0.41	10.328^a	0.011	0.76±0.15	16.605^a	< 0.001
无	76	1.42±0.23			0.22±0.06
注：^a为t值，^b为F值。

下载: 导出CSV

表 3 miR-330-3p与AXIN1295aa对胃癌患者死亡风险的预测价值分析

Table 3. Prediction value analysis of miR-330-3p and AXIN1295aa for mortality risk in gastric cancer patients

项目	AUC	P值	截断值	灵敏度 (%)	特异度 (%)
miR-330-3p	0.748	0.001	1.61	73.769	70.834
AXIN1295aa	0.762	< 0.001	0.51	75.280	74.452
联合检测	0.846	< 0.001		84.115	65.608

下载: 导出CSV

参考文献(17)

[1]	NIEMINEN A A, KONTTO J, PUOLAKKAINEN P, et al. Long-term gastric cancer risk in male smokers with atrophic corpus gastritis[J]. Scand J Gastroenerro, 2019, 54(2): 145-151. doi: 10.1080/00365521.2019.1566492
[2]	秦新裕. 2020年胃癌临床诊治研究进展[J]. 中华胃肠外科杂志, 2021, 24(1): 23-26. QIN X Y. Research progression in clinical treatment of gastric cancer in 2020[J]. Chinese Journal of Gastrointestinal Surgery, 2021, 24(1): 23-26.
[3]	何长征, 宋建霖, 胡时栋, 等. miRNAs用于肿瘤诊治研究的临床试验进展[J]. 解放军医学院学报, 2020, 41(12): 1265-1269. HE C Z, SONG J L, HU S D, et al. Review in clinical trials related to miRNAs in diagnosis and treatment of cancer[J]. Academic Journal of Chinese PLA Medical School, 2020, 41(12): 1265-1269.
[4]	华勇, 张秉丽, 李有连. AXIN和METTL14在胃癌组织中的表达情况及其与患者临床特征的关系[J]. 癌症进展, 2019, 17(19): 2317-2320, 2355. HUA Y, ZHANG B L, LI Y L. Expression of axin and METTL14 in gastric cancer tissues and the relationship with patients' clinical characteristics[J]. Oncology Progress, 2019, 17(19): 2317-2320, 2355.
[5]	RODERS S J, HAMILA S A, MITCHELL C A, et al. A late endosome signaling hub that couples PI3Kα and WNT/β-catenin signaling in breast cancer[J]. Mol Cell Oncol, 2021, 8(4): 152-160.
[6]	KINA S, IWAKAWA R K, MIUAMOTO S, et al. A molecular signature of well-differentiated oral squamous cell carcinoma reveals a resistance mechanism to metronomic chemotherapy and novel therapeutic candidates[J]. J Drug Target, 2021, 29(10): 1118-1127. doi: 10.1080/1061186X.2021.1929256
[7]	曹毛毛, 李贺, 孙殿钦, 等. 2000-2019年中国胃癌流行病学趋势分析[J]. 中华消化外科杂志, 2021, 20(1): 102-109. CHAO M M, LI H, SHUN D Q, et al. Epidemiological trend analysis of gastric cancer in China from 2000 to 2019[J]. Chinese Journal of Digestive Surgery, 2021, 20(1): 102-109.
[8]	郭鉴婷, 陈俊. 进展期胃癌患者预后的影响因素[J]. 中国卫生工程学, 2021, 20(1): 78-79. GUO J T, CHEN J. Factors affecting the prognosis of advanced gastric cancer patients[J]. Chinese Journal of Public Health Engineering, 2021, 20(1): 78-79.
[9]	IKEGAME K, HIKAGE M, FUJIYA K, et al. The effect of minimally invasive gastrectomy for gastric cancer on postoperative gallstone formation[J]. World J Surg, 2021, 45(11): 3378-3385.
[10]	SUNAKAWA Y, MATOBA R, INOUE E, et al. O-13 Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: the DELIVER trial (JACCRO GC-08)[J]. Ann Oncol, 2021, 32(5): S223-S224.
[11]	LØVEBDORF M B, SKOV L. miRNAs in inflammatory skin diseases and their clinical implications[J]. Expert Rev Clin Immu, 2015, 11(4): 467-477.
[12]	张俏, 周学志, 程赛, 等. 外周血炎性指标在晚期胃癌免疫检查点抑制剂治疗效果及预后价值中的临床研究[J]. 中华全科医学, 2024, 22(2): 198-201, 243. doi: 10.16766/j.cnki.issn.1674-4152.003364 ZHANG Q, ZHOU X Z, CHENG S, et al. Clinical study on the therapeutic effect and prognostic value of peripheral blood inflammatory indexes in the treatment of advanced gastric cancer with immune checkpoint inhibitors[J]. Chinese Journal of General Practice, 2024, 22(2): 198-201, 243. doi: 10.16766/j.cnki.issn.1674-4152.003364
[13]	KIM E J, KIM M, SEO S, et al. Comparison of sinusoidal obstruction syndrome in gastric cancer patients receiving S-1/oxaliplatin versus capecitabine/oxaliplatin[J]. Anticancer Res, 2021, 41(1): 391-402.
[14]	TOKUMARU S, KOIZUMI T, SEKINO Y, et al. Lymphocyte-to-monocyte ratio is a predictive biomarker of response to treatment with nivolumab for gastric cancer[J]. Oncology, 2021, 99(10): 1-9.
[15]	程丛丛, 李云秀, 袁海涛, 等. Wnt/β-catenin通路成分Axin和TCF4在卵巢癌中的研究进展[J]. 中国生育健康杂志, 2021, 32(1): 83-84, 101. CHENG C C, LI Y X, YUAN H T, et al. Research progress on Wnt/β-ccatenin pathway components Axin and TCF4 in ovarian cancer[J]. Chinese Journal of Reproductive Health, 2021, 32(1): 83-84, 101.
[16]	MAJDOUBI R, MASMOUDI L, ELHARIF A. Analysis of soil compaction under different wheel applications using a dynamical cone penetrometer[J]. J Terramechanics, 2024, 111(2): 21-30.
[17]	王近瑜, 李国平. circ0006152/miR-557/Wnt3a信号轴在非小细胞肺癌A549细胞发生发展中的机制[J]. 中华全科医学, 2024, 22(3): 418-423. doi: 10.16766/j.cnki.issn.1674-4152.003416 WANG J Y, LI G P. Mechanism of circ0006152/miR-557/Wnt3a signal axis in the genesis and development of non-small cell lung cancer A549 cells[J]. Chinese Journal of General Practice, 2024, 22(3): 418-423. doi: 10.16766/j.cnki.issn.1674-4152.003416